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Abstract
Background: C1q nephropathy (C1qN) was first described as glomerular disease characterized by predominant meangial
C1q deposits in patients with proteinuria and no evidence of systemic lupus erythematosus. Several studies, however,
revealed the clinical heterogeneity of C1qN, showing some cases with normal urinalysis. To confirm the existence of cases
with predominant mesangial C1q deposits and negative or mild proteinuria and/or hematuria, we investigated renal graft
biopsy specimens showing negative to mild proteinuria (less than or equal to 1+ by dip stick test) and/or hematuria.
Methods: Eligible participants were kidney transplant cases who corresponded to the criteria for C1qN and were followed
more than 10 years. Their medical records were reviewed to determine the age at detection of predominant mesangial
C1q deposits, gender, original renal disease and reason for renal graft biopsy, blood pressure, degree of proteinuria and
hematuria, and serum creatinine levels.
Results: From 414 cases in adults and children, five pediatric patients (the male to female ratio, 1:1.5) were eligible. At
the time when predominant mesangial C1q deposits were detected, 2 cases presented with mild proteinuria without
hematuria, but the other 3 cases showed normal urinalysis. Light microscopy revealed minor glomerular abnormality in
all the cases. Immunofluorescent study showed predominant mesangial C1q deposits with IgG, IgM and C3 in all cases.
All selected specimens presented electron dense-depos in the mesangium. Ten years later from the detection, 2 cases
continued to be normal urinalysis and 3 cases had mild proteinuria without hematuria. During this follow-up period,
no cases presented with persistent proteinuria and/or hematuria greater than or equal to 2+ by dip stick test. And no
cases developed systemic lupus erythematosus. Follow-up renal graft biopsies were performed once in 2 cases 8 years
later from the detection. They showed minor glomerular abnormalities. C1q deposit disappeared in one case. In another
case, immunofluorescent study was not examined.
Conclusions: This long-term observational study on transplanted kidneys confirms the existence of cases with
predominant but silent C1q deposits in the mesangium who have negative or mild proteinuria.
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Background
C1q nephropathy (C1qN) was described by Jennette and
Hipp in 1985 [1, 2]. It is characterized by the following cri-
teria: (i) the presence of predominant or co-dominant
mesangial C1q deposits detected by immunofluorescence
microscopy (IF), (ii) corresponding mesangial or para-
mesangial electron-dense deposit (EDD), and (iii) absence
of clinical and serological evidence of systemic lupus ery-
thematosus (SLE). Clinically, patients have proteinuria in
the nephrotic range and it is resistant to steroid treatment.
Clinicopathologic findings of C1qN have accumulated
from various reports [3–5]. One study identified some
cases with normal urinalysis and predominant mesangial
C1q deposits [6].
To confirm the existence of cases with predominant
mesangial C1q deposits and negative to mild proteinuria
and/or hematuria, we investigated cases with renal graft
biopsied specimens who had negative to mild protein-
uria and/or hematuria.
Methods
Selection criteria
We investigated 414 serial cases with negative to mild
proteinuria (less than or equal to 1+ by dip stick test)
and/or hematuria (less than or equal to 1+ by dip stick
test) who received renal transplantations. Renal graft bi-
opsy specimens from cases were obtained between 2002
and 2005 at the Kidney Center in Tokyo Women’s Med-
ical University. The cases consisted of 334 adults aged
19 years old or older, and 80 children aged 2 to less than
or equal to 18 years. There were 242 males and 172
females.
Cases were selected if they had predominant mesangial
C1q deposits (2+ or greater on a ± 4 scale) by the defin-
ition of C1qN [1, 2, 6], and if the follow-up period was
more than 10 years since the predominant C1q deposits
in the mesangium were detected.
We excluded cases with morphologic features of mem-
branoproliferative glomerulonephritis type I [1, 6] or
that fulfilled the diagnostic criteria for SLE [7] because
they show mesangial C1q deposits.
Clinical data and laboratory results
The patients’ medical records were reviewed, noting the
age at detection of predominant mesangial C1q deposits,
gender, original renal disease, reason for renal graft bi-
opsy, and blood pressure levels. The laboratory results
for the following tests were also reviewed: degree of pro-
teinuria and hematuria, anti-C1q antibody titers, and
serum creatinine levels. Additionally, data on medica-
tions was collected including use of steroids, immuno-
suppressants, angiotensin receptor blockers (ARBs), and
angiotensin converting enzyme inhibitors.
Pathologic findings
All specimens were examined by light microscopy (LM;
hematoxylin-eosin, periodic acid-Schiff, and periodic-
methenamine silver), IF (polyclonal rabbit anti-human
IgG, IgM, IgA, C1q, and C3 antibody, Dako, Denmark),
and electron microscopy (EM) according to standard
techniques. Each glomerular tissue specimen was avail-
able for all three methods of evaluation for the detection
of predominant mesangial C1q deposits. The degree of
IF staining was graded as − (negative), ± (trace), 1+
(mild), 2+ (moderate), 3+ (marked), and 4+ (heavy)
according to Jennette’s criteria [1, 2, 6].
Results
Eligible cases, clinical data, and laboratory results
Five pediatric patients (the male to female ratio, 1:1.5) at
selection met the criteria for C1qN [1, 2, 6]. Samples
from these 5 patients constituted 0.01% of all samples
investigated.
The original renal diseases consisted of renal hypopla-
sia, focal segmental glomerulosclerosis (FSGS), auto-
somal recessive polycystic kidney disease, Alport
syndrome, and chronic tubulointerstitial nephritis. All 5
patients received kidney transplantation (kidneys do-
nated by their living parents) at a mean age of 8.8 years
(SD 2.2). Reasons for renal graft biopsies at the time
when predominant C1q deposits were detected were due
to protocol in 4 cases, and mild proteinuria in 1 case
(Table 1). Protocol renal graft biopsies were carried out
an average of 2.2 times (range, 1 to 3 times) before pre-
dominant mesangial C1q deposits were detected. No
case presented with hypertension [8] or signs or symp-
toms of infection when predominant mesangial C1q
deposits were detected. The follow-up period after the
detection of predominant C1q deposits ranged from 10
to 11 years.
When predominant mesangial C1q deposits were de-
tected, 2 cases presented with mild proteinuria (1+ by
dipsticks) without hematuria, but the other 3 cases
showed normal urinalysis results (Table 1).
All eligible cases had anti-C1q antibody titers in the
normal range (reference anti-C1q antibody titer, less
than 2.2 μg/mL) [9]. 4 cases had normal serum creatin-
ine levels and stable renal function. One case had a
moderate increase in serum creatinine level (from 0.5 to
1.2 mg/dL) due to acute rejection 11 months after renal
transplantation. After that, the patient maintained stable
renal function.
During the follow-up period, no cases presented with
persistent proteinuria and/or hematuria greater than or
equal to 2+ by dip stick test. Additionally, no cases pre-
sented with hypertension or developed SLE.
These 5 patients were given immunosuppressive agents
against rejection as follows: tacrolimus hydrate (adjusted to
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target level of 3–5 ng/mL), mycophenolate mofetil
(700 mg/m2/day), and methylprednisolone (1 to 4 mg/day).
At the time of diagnosis, 2 cases had received an ARB,
losartan potassium, at 100 mg/day or 25 mg/day, re-
spectively. All cases had received ARBs 10 years after
the predominant C1q deposits were detected (Table 2).
No cases had received angiotensin converting enzyme
inhibitors at the time of detection of predominant
mesangial C1q deposits or 10 years later.
Pathologic findings
Details of LM, IF EM findings are presented in Table 1.
Averages of 28 glomeruli (10 to 63 glomeruli) were ob-
served with LM; all these glomeruli showed minor glom-
erular abnormalities (MGA) (Table 1, Fig. 1a).
IF revealed predominant mesangial C1q deposits and
co-deposits (Table 1, Fig. 1b). C1q deposits were limited
to the mesangium or para-mesangium areas, except for 1
case whose specimen also exhibited staining in some ca-
pillary loops. Equal or less intense mesangial IgG, IgM,
and C3 deposits were detected in all selected specimens
(Table 1). IgA deposits were observed only in 1 case.
All selected specimens showed EDDs in the mesan-
gium on EM (Table 1, Fig. 1c). Subendothelial deposits
were observed in 1 case and subepithelial deposits were
observed in 2 cases. No specimens showed tubuloreticu-
lar inclusions or foot process effacements.
Two cases had biopsies of their native kidneys before
renal transplantation, but did not present with mesangial
C1q deposits and EDDs. Renal graft biopsy specimens
from transplanted kidneys at renal transplantation in
these 5 cases were absent of C1q deposits and EDDs.
In 2 cases, follow-up renal graft biopsies after C1q de-
tection on mesangium were performed once 8 years later
in case (Table 2). Their glomeruli presented with MGA
in the LM studies. The IF study in 1 case was negative
for C1q, IgG, IgM, IgA, and C3 (Table 2, Fig. 1d and e).
In another case, the IF study was not examined.
Discussion
This long-term observational study on transplanted kid-
neys confirms the existence of cases with predominant
but silent C1q deposits in the mesangium who have
negative or mild proteinuria with MGA.
Said et al. reported that patients who had predominant
mesangial C1q deposits with MGA on their transplanted
kidneys, had maintained no proteinuria for a mean follow-
up of 1 year [10]. Our study, moreover, demonstrated that
patients who had predominant mesangial C1q deposits
with MGA on their transplanted kidneys, had maintained
Table 2 Clinical and pathologic findings 10 years later
Case No. Laboratory results LM findings IF findings ARB
Up OB sCr [mg/dL]
1 1+ – 1.27 MGA(8 y later) NA candesartan cilexetil 25 mg/day
2 1+ – 1.39 NA NA losartan potassium 100 mg/day
3 – – 1.78 MGA (8 y later) Negative for C1q, IgG,
IgM, IgA and C3
losartan potassium 25 mg/day
4 ± – 0.83 NA NA valsartan 60 mg/day
5 – – 0.80 NA NA losartan potassium 37.5 mg/day
Abbreviation: No number, LM light microscopy, IF immunofluorescent, Up urinary protein, OB occult blood, sCr serum creatinine, MGA minor glomerular ab
normality, NA not available, ARB angiotensin receptor blocker
Table 1 Clinical and pathologic findings at the time when predominant mesangial C1q deposits were detected
Case
No.
Reason for
RBx
Laboratory results LM findings IF findings EM findings
Up OB sCr [mg/dL] IgG IgM IgA C1q C3 Mes Subend Subep ARB
1 Protocol (−) (−) 0.7 MGA 2+ 1+ 1+ 2+ 1+ (+) (−) (+) –
2 Protocol (+) (−) 0.6 MGA 2+ 1+ – 2+ 1+ (+) (−) (−) losartan potassium
100 mg/day
3 Protocol (−) (−) 1.2 MGA 2+ 1+ – 2+ 1+ (+) (+) (−) –
4 Mild
proteinuria
(+) (−) 0.7 MGA 2+ 2+ – 2+ 1+ (+) (−) (−) –
5 Protocol (−) (−) 0.6 MGA 1+ 1+ – 2+ 1+ (+) (−) (+) losartan potassium
25 mg/day
Abbreviation: No number, RBx renal biopsy, LM light microscopy, IF immunofluorescent, EM electron microscopy, Up urinary protein, OB occult blood, sCr serum
creatinine, MGA minor glomerular abnormality, Mes mesangial deposits, subend subendothelial deposits, Subep subepithelial deposits
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negative to mild proteinuria without hematuria even for
10 years follow-up.
Differences between our eligible cases and previous
reports of C1qN
The age at diagnosis and gender ratio were similar to those
of previous reports of C1qN [1, 2, 4]. Pathologically, the
LM, IF, and EM findings also corresponded to those in
Jennette’s reports (Table 1) [1, 2]. EM showed a similar rate
of occurrence of subendothelial and subepithelial EDDs in
our eligible cases as in those of Jennette’s reports [1, 2, 4].
The prevalence of C1qN differs in various reports, ran-
ging from 0.2 to 1.9% in biopsies from children and
adults [2, 6]. The 0.01% incidence in our sample popula-
tion was less than the incidence of C1qN in previous re-
ports. The reason might be that our study was done in
cases with transplanted kidneys. Renal graft biopsy is
performed repeatedly by protocol, even in patients with
normal urinalysis.
No cases showed FSGS or mesangial proliferative
glomerulonephritis (MesPGN) in our study. As for IgA
deposits, only 1 out of the 5 cases had positive staining,
although 9 cases out of 15 exhibited positive staining in
Jennette’s previously published case series [1, 2]. In this
regard, our eligible cases differ from those in previous
reports of C1qN. These differences might be related to
the negative or mild proteinuria or hematuria observed
in our cases.
Why was normal urinalysis observed in our eligible cases?
Immune complex deposits are thought to cause neph-
ritis by attracting and activating intrinsic glomerular
cells to release local mediators of inflammation [11]. On
the other hand, one report suggested that overt C1qN
would require additional factors in addition to C1q de-
posits. Issac et al. suggested that BK polyoma viral infec-
tion could trigger C1qN [12], although our eligible cases
were not positive for BK polyoma viral infection as
assessed by SV40 T antibody staining in any renal graft
specimens.
C1q deposits might be only innocent bystanders. Wald-
herr et al. reported that patients with IgAN are only the
tip of the iceberg among patients with IgA deposits in
their kidneys because mesangial IgA deposits are found in
approximately 4.8% of the general population, whereas
IgAN was found in 0.02% of the general population [13].
Thus, the prevalence of predominant but silent C1q de-
posits would be higher than that of C1qN.
Although C1qN was previously described as MGA,
FSGS, and MesPGN in LM [1–5], no eligible cases in
the current study presented with FSGS or MesPGN.
This might mean that our eligible cases did not have
C1qN, but only silent C1q deposits, similar to silent pre-
dominant mesangial IgA deposits that present in MGA
[13]. This would also explain the reason for the negative
to mild proteinuria findings in contrast to previous re-
ports of C1qN [1–5].
a b c
d e
Fig. 1 Pathologic findings. a Minor glomerular abnormality. Periodic acid-Schiff stain. Original magnification × 600. b Immunofluorescence detection of
C1q deposits in mesangial areas (2+ intensity). c Electron-dense deposits on mesangial and para-mesangial areas. d and e Minor glomerular abnormality.
Periodic acid-Schiff stain. Original magnification × 200
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Another possibility for why our eligible cases did not
experience abnormal urinalysis is that immunosuppres-
sive therapy against rejection might suppress the inflam-
mation, although Kersnik Levart et al. reported that
cyclosporine A and/or mycophenorate mofetil were not
effective for some cases of C1qN [14].
ARBs could prevent proteinuria; however, 2 cases did
not experience proteinuria before ARBs were adminis-
trated. Moreover, in one of the 2 cases, not only C1q de-
posits but all other deposits were not detected 8 years
later. This suggests the existence of cases with predom-
inant but silent C1q deposits in the mesangium.
Conclusion
This long-term observational study on transplanted
kidneys confirms that there are cases with predominant
but silent C1q deposits in the mesangium who have
negative or only mild proteinuria with MGA. This pro-
vides a first step towards a better understanding of the
role of predominant mesangial C1q deposits.
Additional file
Additional file 1: Pathologic findings. Minor glomerular abnormalities
stained with Periodic acid-Schiff stain. Original magnification × 600.
Immunofluorescence detection of C1q deposits in mesangial areas (2+
intensity). Electron-dense deposits on mesangial and para-mesangial
areas. Minor glomerular abnormality. (PPTX 8948 kb)
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